|Year : 2016 | Volume
| Issue : 4 | Page : 467
|Treatment of chronic spontaneous urticaria with a single dose of omalizumab: A study of four cases
Radhakrishnan Subramaniyan, Ajay Chopra
Department of Dermatology, Command Hospital Air Force, Bengaluru, Karnataka, India
|Date of Web Publication||7-Jul-2016|
Department of Dermatology, Command Hospital Air Force, Old Airport Road, Bengaluru - 560 007, Karnataka
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Chronic spontaneous urticaria (CSU) has a detrimental effect on patients' emotional and physical quality of life. Omalizumab, an anti-immunoglobulin E humanized monoclonal antibody, has been shown to be very effective in the treatment of refractory chronic urticaria patients but may not be an economically viable option for all CSU patients. However, we present a case series where a single dose of omalizumab gave sustained relief of symptoms in patients with CSU, which may be an economical option. Aims: The aim of this study is to assess the efficacy of a single dose of omalizumab in the treatment of CSU. Materials and Methods: Four patients of CSU whose disease was not controlled with four times the licensed dose of tablet fexofenadine 180 mg were exhibited one subcutaneous injection of omalizumab and were followed up at 4 weekly intervals for 24 weeks for Weekly Urticaria Activity Score 7 (UAS7) and Dermatology Life Quality Index (DLQI). Results: A sharp decline in UAS7 and DLQI was documented in 7-10 days. The decline was maintained up to 16 weeks in one case and 20 weeks in the other three cases. Both the scores at the end of the follow-up period of 24 weeks were better than the pre-omalizumab scores. Conclusion: The results of this case series indicate the efficacy of a single-dose omalizumab in treating moderate to severe refractory CSU. Further studies are required to identify the minimum frequency of administering omalizumab to effectively control CSU. This would greatly reduce the cost of this novel therapy.
Keywords: Chronic spontaneous urticaria, Dermatology Life Quality Index, omalizumab, Urticaria Activity Score 7
|How to cite this article:|
Subramaniyan R, Chopra A. Treatment of chronic spontaneous urticaria with a single dose of omalizumab: A study of four cases. Indian J Dermatol 2016;61:467
|How to cite this URL:|
Subramaniyan R, Chopra A. Treatment of chronic spontaneous urticaria with a single dose of omalizumab: A study of four cases. Indian J Dermatol [serial online] 2016 [cited 2021 Jan 27];61:467. Available from: https://www.e-ijd.org/text.asp?2016/61/4/467/185745
What was known?
Monthly injections of omalizumab are approved as the third line management in moderate to severe chronic spontaneous urticaria.
| Introduction|| |
Chronic spontaneous urticaria (CSU) is a debilitating skin condition characterized by the spontaneous appearance of wheals, angioedema, or both occurring intermittently or continuously for more than 6 weeks due to known or unknown causes.  It impacts millions of patients worldwide. CSU is thought to have the most impact on quality of life of any allergic disease and is similar in severity to triple-vessel coronary artery disease. , The condition generally has a prolonged duration of 1-5 years, persisting for more than 5 years in 11-14% of patients  and has a detrimental effect on patients' emotional and physical health-related quality of life. ,
Omalizumab, an anti-immunoglobulin E (IgE) humanized monoclonal antibody, has now been shown to be very effective in the treatment for CSU, in case reports, case series, as well as in double-blind, placebo-controlled studies, in antihistamine refractory chronic urticaria patients. ,,,,,,, At present, it is being recommended as the third-line treatment option in the management of CSU by the European Academy of Allergy and Clinical Immunology (EAACI).  It is felt that omalizumab may not be an economically viable option for all CSU patients.  However, we present a case series where a single dose of omalizumab gave sustained relief of symptoms in patients with CSU, which may be an economical option.
| Materials and Methods|| |
Four patients with CSU whose disease was not controlled with up to four times the licensed dose of tablet fexofenadine 180 mg, and out of which two patients also did not show a good response to cyclosporine A, were treated off-label with a single dose of 300 mg omalizumab. At the initial visit, complete history, physical examination, and clinical assessment of urticaria and angioedema were done. Laboratory evaluations included complete blood count, erythrocyte sedimentation rate, liver function test, kidney function test, stool evaluation for parasites, thyroid function test, anti-thyroglobulin antibody, total IgE, and autologous serum skin test. In addition, electrocardiogram, chest X-ray, hepatitis B and C serologies, HIV 1 and 2 antibodies, antinuclear antibody test, cryo-agglutinins, and complement levels were also carried out. All the results were within the normal range or negative. Physical urticarias, urticarial vasculitis, pregnancy, lactation, renal dysfunction, history of epilepsy, malignancy, and stroke were ruled out.
A 2-week screening period was used to confirm Urticaria Activity Score 7 (UAS7) and Dermatology Life Quality Index (DLQI) (ranging from 0 to 30, with higher scores indicating a worse quality of life). All patients maintained a daily diary to record urticarial signs and symptoms based on a scoring system [Table 1].  None of the patients had satisfactory response to a maximal dose (four times the licensed dose) of H1-blocker therapy. The patients were also exhibited short courses of tablet prednisolone 30 mg/day for a week whenever they had acute exacerbations as per guidelines. 
|Table 1: The Urticaria Activity Score 7 for assessing disease activity in chronic urticaria |
Click here to view
Thereafter, patients were gradually weaned off other medication excluding H1-blockers 4 weeks before the administration of omalizumab. At the end of this 4-week period, a single dose of 300 mg was administered as a subcutaneous injection with necessary precautions to handle possible anaphylaxis and other adverse effects.
Patients were then followed up at 4 weekly intervals over 24 weeks. Daily records for urticaria signs and symptoms were maintained throughout the follow-up period. The response to treatment was assessed at these visits based on the weekly UAS7 and DLQI during each visit. Patients were permitted to take 180 mg fexofenadine on required basis. The use of fexofenadine was tabulated at each visit.
| Results|| |
We treated four patients with moderate to severe refractory CSU with a single dose of 300 mg omalizumab at the Department of Dermatology, Command Hospital Air Force, Bengaluru, and followed them up over 6 months. Informed consent was obtained from all the patients before starting the treatment. Patient demographics and clinical characteristics are summarized in [Table 2].
There was a significant improvement in all the four patients. After the initial 7-10 days, a sharp decline in UAS7 and DLQI was documented. This decline was maintained for the next 16 weeks when Case 3 first showed relapse of urticaria with UAS7 increasing followed by the other three patients relapsing at 20 weeks. The UAS7 and DLQI over the follow-up period are shown in [Table 3] and [Table 4], respectively. Both the scores at the end of the follow-up period of 24 weeks were better than the pre-omalizumab scores.
During the entire follow-up period, the patients were managed only with tablet fexofenadine 180 mg on required basis. No adjuvant immunosuppressants were prescribed. Case 3 suffered from a single episode of an acute flare at 20 weeks which was managed with a short course of oral prednisolone as per guidelines.  However, no attacks of angioedema were observed in Case 3 in the follow-up period. Apart from a mild transient injection site reaction in Case 1, no other adverse reactions of the drug were observed.
| Discussion|| |
Omalizumab is effective in CSU of doses from 150 to 300 mg/month as per the EAACI 2013 guidelines.  We wanted to assess the efficacy of a single dose of 300 mg omalizumab, in patients with severe chronic urticaria not responding to recommended therapies and often requiring systemic steroids to control exacerbations. It was observed that omalizumab had a rapid onset of action in the treatment of refractory CSU with a rapid decrease in UAS7 within 2 weeks of administration. This rapid response and decline in UAS7 are in agreement with that observed in previous studies. , The declining UAS7 trend continued till the end of 24 weeks follow-up period [Figure 1].
|Figure 1: Graphical description of Urticaria Activity Score 7 over the 24-week period|
Click here to view
The DLQI showed a correlation with the UAS7. A marked improvement was observed within the first 2 weeks and the response was sustained till the end of 24 weeks period [Figure 2].
|Figure 2: Graphical description of Dermatology Life Quality Index over the 24-week period|
Click here to view
We would like to highlight the fact that both the UAS7 and DLQI at 24 weeks were below the baseline scores. Moreover, post-omalizumab, the urticarial episodes became more responsive to tablet fexofenadine and overall reduction in the use of rescue medication was noted. The frequency of intake of fexofenadine dropped to 1-2 tablets of fexofenadine 180 mg/week.
Case 3 was the first patient to show a return of urticarial lesions at 16 weeks. It is interesting to note that this patient's IgE level was the lowest among all the patients prior to omalizumab. Since omalizumab is an anti-IgE antibody, this patient whose IgE levels were the least probably showed the weakest response to omalizumab. Although raised IgE levels are not mandatory for administration of omalizumab in CSU unlike in bronchial asthma where the dosage of the drug is dependent on IgE levels,  it is possible that patients of CSU whose IgE levels are normal have other mechanisms causing the urticaria and so may not benefit as much as patients with high-IgE levels.
The mechanism by which omalizumab improves urticaria has not been fully elucidated. It has been reported that patients with active CSU have abnormal basophil function, including suppression of the high-affinity IgE receptor (Fc"RI) pathway (related to altered expression of src homology 2 - containing inositol phosphatase), blood basopenia, and recruitment of basophils to skin-lesion sites. In patients with CSU in remission, blood basopenia and suppressed Fc"RI function revert toward normal.  Effect on mast cell survival might be responsible for the continued slower response after the initial rapid response as observed in our cases as well as the previous studies. ,
Although omalizumab is increasingly becoming a widely accepted treatment modality for refractory CSU patients, the high cost of the recommended regimen of monthly dosing curbs its use in the Indian scenario. However, as is evident from our experience, even a single dose of 300 mg omalizumab is sufficient to produce significant remission and decrease in UAS7 and usage of rescue medication in patients with refractory CSU. This translated into a better overall therapeutic response and a substantial improvement in the DLQI.
We recommend that randomized control trials can be carried out to assess the minimum effective frequency of injection omalizumab which is required to achieve disease remission and thereafter, maintain the improved UAS7 scores and DLQI using conventional medication. This would make this novel therapy more accessible to the patients who need it the most.
| Conclusion|| |
The results of this study of four cases indicate the efficacy of a single-dose omalizumab in treating moderate to severe refractory CSU. The limitation of this study is that it is only a case series of four cases. Further randomized controlled trials on larger samples are required to identify the minimum frequency of administering omalizumab to effectively control CSU. This would greatly reduce the cost of this novel therapy.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al.
The EAACI/GA (2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: The 2013 revision and update. Allergy 2014;69:868-87.
O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136:197-201.
Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999;140:667-71.
Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, et al.
Clinical and laboratory parameters in predicting chronic urticaria duration: A prospective study of 139 patients. Allergy 2004;59:869-73.
Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al.
Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy 2011;66:317-30.
Kang MJ, Kim HS, Kim HO, Park YM. The impact of chronic idiopathic urticaria on quality of life in Korean patients. Ann Dermatol 2009;21:226-9.
Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99:190-3.
Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res 2012;4:326-31.
Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol 2012;12:406-11.
Ivyanskiy I, Sand C, Thomsen SF. Omalizumab for chronic urticaria: A case series and overview of the literature. Case Rep Dermatol 2012;4:19-26.
Büyüköztürk S, Gelincik A, Demirtürk M, Kocaturk E, Colakoglu B, Dal M. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: A real life survey. J Dermatol 2012;39:439-42.
Godse KV. Omalizumab in treatment-resistant chronic spontaneous urticaria. Indian J Dermatol 2011;56:444.
Godse K, Mehta A, Patil S, Gautam M, Nadkarni N. Omalizumab - A review. Indian J Dermatol 2015;60:381-4.
Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria. Allergy Asthma Proc 2013;34:446-52.
Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al.
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73.e1.
Magerl M, Staubach P, Altrichter S, Ardelean E, Krause K, Metz M, et al.
Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010;126:665-6.
Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol 2008;20:709-16.
Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, et al.
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202-9.e5.
What is new?
- Even a single dose of omalizumab gives sustained improvement in chronic spontaneous urticaria (CSU) with lowering of the Urticaria Activity Score 7 and Dermatology Life Quality Index up to 24 weeks
- More studies will be required to determine the minimum frequency of dosing with omalizumab for it to be both economical and effective in CSU.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3], [Table 4]
| Article Access Statistics|
| Viewed||2191 |
| Printed||14 |
| Emailed||0 |
| PDF Downloaded||87 |
| Comments ||[Add] |